ProsTACT-Global-203

A Multinational, Multicenter, Prospective, Randomized, Controlled, OpenLabel, Phase 2/3 Study of Lutetium Rosopatamab Tetraxetan plus Standard of Care vs. Standard of Care alone for Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously Treated Androgen Receptor Pathway Inhibition.

Enquire

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate cancer

Study Phase

II-III

Trial Identifiers

NCT06520345

https://clinicaltrials.gov/study/NCT06520345

GenesisCare Location(s)

GenesisCare Murdoch

Principal Investigator(s)

Dr Aviral Singh

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

ProsTACT-Global-203

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare AU

Website policies

Contact us

Media & Social